摘要
目的观察氨氯地平联合厄贝沙坦治疗透析高血压的疗效。方法选择82例透析高血压患者共,将患者随机分为治疗组和观察组各41例,观察组每日晨起餐后口服苯磺酸氨氯地平片和厄贝沙坦片150 mg。对照组患者仅口服苯磺酸氨氯地平。2组患者均治疗6个月。观察2组治疗后的透析间期和透析过程中的收缩压(systolic blood pressure,SBP)、舒张压(diastolic blood pressure,DBP)、平均动脉压(mean arterial pressure,MAP)和肾功能。结果经不同方案治疗6个月后,观察组患者透析间期和透析过程中的SBP、DBP、MAP改善情况优于对照组(P<0.05);观察组24小时尿蛋白定量减少水平明显优于对照组(P<0.05)。结论氨氯地平联合厄贝沙坦治疗透析高血压效果明显优于单用氨氯地平,可明显控制透析间期和透析过程中的血压。
Objective To observe the curative effect of amlodipine combined with irbesartan in the treatment of hypertension in dialysis. Methods A total of 82 cases patients with hypertension,were randomly divided into treatment group and observation group,with 41 cases in each group,observation group oral benzene sulfonic acid amlodipine tablets and irbesartan. Patients in the control group were treated with oral amlodipine. Two groups of patients were treated for 6 months. The systolic blood pressure（ SBP）,diastolic blood pressure（ DBP）,mean arterial pressure（ MAP） and serum renal function were observed in the two groups after treatment. Results After the different schemes for treatment of 6 months,the observation group patients during dialysis and dialysis interval SBP,DBP,MAP were better than the control group（ P〈0. 05）; the observation group of 24 hours urine protein level reduced significantly better than the control group（ P〈0. 05）. Conclusion Amlodipine combined with irbesartan in treatment of dialysis hypertension effect is superior to the single amlodipine,can obviously control the blood pressure in dialysis interval and process.
出处
《中国生化药物杂志》
CAS
2016年第3期73-75,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
氨氯地平
厄贝沙坦
透析高血压
amlodipine
irbesartan
hypertension in dialysis
